PYXS — Pyxis Oncology Inc
NASDAQ · Healthcare · Biotechnology
$3.50
+$0.06 (+1.74%)
Pyxis Oncology Inc (PYXS) is a biotechnology company listed on NASDAQ. It is led by Thomas Civik, based in 321 Harrison Avenue, Boston, MA, United States, 02118, with about 56 employees. Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Latest reported PYXS revenue for 2025-09-30 was $2.8M. Net income was -$22.0M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. PYXS currently screens at market cap $109.6M.
Use this PYXS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PYXS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PYXS SEC filings page. Lician reads the product cache first so this HTML stays unique to Pyxis Oncology Inc even when a live quote feed is slow.
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
PYXS Key Statistics
Market Cap
$109.60M
Volume
421,974
Previous Close
$2.96
Day Range
$2.94 – $3.09
P/B Ratio
3.53
EPS
-$1.32
Revenue
$16.15M
Net Income
-$77.33M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-478.9%
Employees
56
PYXS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $16.15M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$77.33M | -$73.79M | -$120.72M | -$75.97M |
| EPS (Diluted) | -$1.32 | -$1.85 | -$3.65 | -$8.95 |
Total Assets
$157.18M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$19.47M
Operating Cash Flow
-$57.67M
Free Cash Flow
$0.00
Pyxis Oncology Inc Company Information
- Interim CEO & Director
- Thomas Civik
- Headquarters
- 321 Harrison Avenue, Boston, MA, United States, 02118
- Website
- www.pyxisoncology.com
- Phone
- 617 453 3596
- IPO / Founded
- 2021-10-08
- Sector
- Healthcare
- Industry
- Biotechnology